SCHEDULE OF LOSS BEFORE TAXES ON INCOME |
SCHEDULE
OF LOSS BEFORE TAXES ON INCOME
| |
2025 | | |
2024 | |
| |
Year
ended July 31, | |
| |
2025 | | |
2024 | |
| |
| |
Domestic | |
$ | (23,999,920 | ) | |
$ | 23,946,952 | ) |
Foreign | |
| (2,556,220 | ) | |
| (28,878,500 | ) |
|
SCHEDULE OF EFFECTIVE INCOME TAX |
SCHEDULE
OF EFFECTIVE INCOME TAX
| |
2025 | | |
2024 | |
| |
Year
ended July 31, | |
| |
2025 | | |
2024 | |
| |
| | |
| |
Expected income tax (recovery) expense | |
| (7,170,160 | ) | |
| (1,331,518 | ) |
Tax rate changes and effect of taxes of subsidiaries
at foreign rates | |
| 1,448,710 | | |
| 1,467,021 | |
Share-based compensation and other non-deductible
expenses | |
| 240,070 | | |
| 1,697,204 | |
Share issuance cost booked directly to equity | |
| (375,750 | ) | |
| - | |
Adjustments in respect of prior periods | |
| 868,490 | | |
| - | |
R&D Credits | |
| (1,284,010 | ) | |
| (3,903,153 | ) |
Effect of spin-out transaction | |
| - | | |
| (297,781 | ) |
Valuation allowance | |
| 6,272,650 | | |
| 2,368,228 | |
Income tax (recovery) | |
$ | - | | |
$ | - | |
|
SCHEDULE OF DEFERRED TAX ASSETS NET |
SCHEDULE
OF DEFERRED TAX ASSETS NET
| |
2025 | | |
2024 | |
| |
July
31, | |
| |
2025 | | |
2024 | |
Deferred Tax Assets: | |
| | | |
| | |
Property and
equipment | |
$ | 730 | | |
| 731 | |
Marketable Securities | |
| 11,760 | | |
| 15,678 | |
Intellectual property | |
| 260,860 | | |
| 256,741 | |
Warrant liability | |
| - | | |
| - | |
Share issuance costs | |
| 310,230 | | |
| 376,978 | |
Investment in BC Therapeutics | |
| 44,650 | | |
| 19,172 | |
Operating tax losses carried
forward | |
| 5,067,840 | | |
| 4,850,799 | |
Operating tax losses carried
forward- USA | |
| 8,494,300 | | |
| 5,545,125 | |
Research and Development | |
| 14,240,640 | | |
| 10,879,373 | |
Total deferred tax assets | |
| 28,431,010 | | |
| 21,944,597 | |
Valuation allowance | |
| (24,329,720 | ) | |
| (18,034,710 | ) |
Net deferred tax assets | |
$ | 4,101,290 | | |
$ | 3,909,887 | |
| |
| | | |
| | |
Deferred Tax Liability: | |
| | | |
| | |
Intellectual Property | |
$ | - | | |
$ | - | |
Warrant liability | |
| (4,053,520 | ) | |
| (3,848,762 | ) |
Property,
plant, and equipment | |
| (47,770 | ) | |
| (61,125 | |
Total net deferred tax liabilities | |
| (4,101,290 | ) | |
| (3,909,887 | ) |
Valuation allowance | |
| - | | |
| - | |
Net deferred tax assets
(liabilities) | |
$ | - | | |
$ | - | |
|